{"Clinical Trial ID": "NCT00077857", "Intervention": ["INTERVENTION 1:", "1250 mg/m2 Capecitabine + Docetaxel", "1 250 mg/m^2 of capecitabine (Xeloda\u00ae) orally twice daily on days 1 to 14 of each 3-week cycle, in combination with docetaxel (Taxotere\u00ae) 75 mg/m^2 intravenously on day 1 of each 3-week cycle.", "INTERVENTION 2:", "- 825 mg/m2 Capecitabine + Docetaxel", "825 mg/m^2 of capecitabine orally twice daily on days 1 to 14 of each 3-week cycle, in combination with docetaxel 75 mg/m^2 intravenously on day 1 of each 3-week cycle."], "Eligibility": ["Incorporation criteria:", "Women >=18 years of age;", "- Target lesion >=1;", "Locally advanced or metastatic breast cancer;", "Resistance to anthracycline has been demonstrated;", ">=2 chemotherapy regimens for advanced/metastatic diseases.", "- Exclusion criteria:", "Prior treatment with Xeloda, continuous infusion of 5-fluorouracil or other oral fluoropyrimidines;", "Previous treatment with paclitaxel or docetaxel for advanced/metastatic disease."], "Results": ["Performance measures:", "Time of progression of disease or death", "The progression-free survival was defined as the period from the date of randomization to the day of the progression or documented death of the disease due to any cause.", "Duration: Directed event (after 350 events) Median observation time was approximately 16 months.", "Results 1:", "Title of arm/group: 1250 mg/m^2 Capecitabine + Docetaxel", "Description of the arm/group: 1250 mg/m^2 capecitabine (Xeloda) orally twice daily on days 1 to 14 of each 3-week cycle, in combination with docetaxel (Taxotere) 75 mg/m^2 intravenously on day 1 of each 3-week cycle.", "Total number of participants analysed: 230", "Median (95% confidence interval)", "Unit of measure: Month 7.9 (6.9 to 8.5)", "Results 2:", "Title of arm/group: 825 mg/m^2 Capecitabine + Docetaxel", "Description of the arm/group: 825 mg/m^2 of capecitabine orally twice daily on days 1 to 14 of each 3-week cycle, in combination with docetaxel 75 mg/m^2 intravenously on day 1 of each 3-week cycle.", "Total number of participants analysed: 229", "Median (95% confidence interval)", "Unit of measure: Month 5.8 (4.9 to 7.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 41/217 (18.89 per cent)", "13/217 (5.99 per cent)", "Neutropenia 6/217 (2.76%)", "- Leukopenia 2/217 (0.92%)", "Anemia 0/217 (0.00 %)", "Atrial flutter rate 0/217 (0.00 %)", "- Heart failure 0/217 (0.00 %)", "Cardiogenic shock 1/217 (0.46%)", "Cardiopulmonary impairment 0/217 (0.00 %)", "Stomatitis every 5/217 (2.30 per cent)", "Diarrhoea 2/217 (0.92%)", "2/217 (0.92%)", "Adverse Events 2:", "Total: 53/248 (21.37 per cent)", "* Febrile neutropenia 14/248 (5.65 per cent)", "- Neutropenia 4/248 (1.61%)", "- Leucopenia 0/248 (0.00 %)", "Anemia 1/248 (0.40%)", "Atrial stop 1/248 (0.40%)", "- Heart failure 1/248 (0.40%)", "Cardiogenic shock 0/248 (0.00 %)", "Cardiopulmonary impairment 1/248 (0.40%)", "- Stomatitis all 0/248 (0.00 %)", "Diarrhoea 2/248 (0.81%)", "2/248 (0.81%)"]}